MedTrace Logo

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

NCT03083743 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 417

Last updated 2017-03-20

No results posted yet for this study

Summary

The trial is to evaluate the efficacy and safety of recombinant human Apo-2 ligand in treating patients with advanced retreated non-small cell lung cancer

Conditions

  • Non-small-cell Lung Cancer (NSCLC) Stage IV

Interventions

BIOLOGICAL

Recombinant human Apo-2 ligand for Injection

150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle

BIOLOGICAL

Placebo

150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle

Sponsors & Collaborators

  • Shanghai Gebaide Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi, Ph.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-10-31
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03083743 on ClinicalTrials.gov